HistoRx and Lilly Extend, Expand AQUA® Analysis Partnership

—Agreement provides Lilly researchers broad access to HistoRx AQUAŽ technology for tissue biomarker analysis —
 
NEW HAVEN, Conn., March 26, 2008— HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE:LLY) to make the HistoRx AQUA® technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA® technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA® technology for tissue biomarker analysis, and HistoRx will develop customized AQUA® analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.

HistoRx provides pharmaceutical and biotechnology companies access to AQUA® technology through partnership agreements by which HistoRx works with the company in applying its hallmark quantitative, multiparametric, tissue-based biomarker measurement and analysis to drug development programs, virtually eliminating the subjective interpretation inherent in conventional immunohistochemical methods. In the course of the partnership, HistoRx develops AQUA® analysis-based diagnostic assays that are linked to its partners’ drugs in development. HistoRx may then commercialize these assays as prognostic tests or as companion diagnostics.

HistoRx currently has 10 such partnerships with leading pharmaceutical companies such as Lilly involving therapeutics in multiple stages of development. Researchers at these companies are using AQUA® analysis-based assays to identify correlations of biomarker expression with clinical outcomes, including drug dosing effects, therapeutic mechanism of action, drug safety, and therapeutic efficacy.

“We consider this expanded agreement with Lilly, one of the world’s leading innovation-driven pharmaceutical companies, to be a tremendous validation of the HistoRx AQUA® technology,” said Rana K. Gupta, CEO of HistoRx. “By revealing stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome, we expect this ongoing partnership to continue providing a substantial boost to Lilly’s drug research and development programs.”

About HistoRx (www.historx.com)
HistoRx, Inc. is a leader in the emerging field of tissue-based diagnostic products for targeted patient treatment. The company’s products and services are based on proprietary AQUA® technology, the first platform capable of measuring biomarker concentration with subcellular resolution in tissue sections in a fully standardized and automated manner. HistoRx partners with pharmaceutical and biotechnology companies to generate precise and cost-effective answers about the safety and effectiveness of targeted therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop companion diagnostic tests that will be co-marketed with partners’ targeted therapeutics. HistoRx also pursues internal programs to develop proprietary diagnostics that will enable improved treatment decisions in cancer care.